Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,331.20
(
0.00%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
106.88
(
-1.56%
)
Bitcoin
67,270.44
(
0.85%
)
News Focus
News Focus
Post# of 257314
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 75562

Thursday, 05/14/2009 8:41:21 PM

Thursday, May 14, 2009 8:41:21 PM

Post# of 257314
GILD sues TEVA on Atripla P-IV challenge:

http://finance.yahoo.com/news/Gilead-Sciences-Files-Second-bw-15249228.html

Inasmuch as Truvada is a component of Atripla, for all practical purposes this is the same lawsuit on the one stemming from Teva’s P-IV challenge against Truvada (#msg-34164531).


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today